Location History:
- L'Aquila, IT (2005 - 2007)
- L'Aquila AQ, IT (2010)
Company Filing History:
3 out of 22 
1 out of 832,891 Years Active: 2005-2010
Title: Vilma Sabbatini: Innovator in Pharmaceutical Chemistry
Introduction
Vilma Sabbatini is a distinguished inventor based in L'Aquila, Italy. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of amides that play a crucial role in the treatment of various inflammatory conditions. With a total of four patents to her name, her work has garnered attention for its potential therapeutic applications.
Latest Patents
Sabbatini's latest patents focus on amides that are useful in inhibiting IL-8-induced chemotaxis of neutrophils. One of her notable inventions includes N-(2-aryl-propionyl)-amides, which are described in detail in her patents. These compounds are designed to prevent and treat tissue damage caused by the excessive recruitment of polymorphonuclear neutrophils at inflammatory sites. Specifically, her work emphasizes the R enantiomers of these amides for their effectiveness in treating conditions such as psoriasis, ulcerative colitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, and rheumatoid arthritis. Another significant patent involves N-(2-aminoaryl-propionyl)-amides, which also target the inhibition of neutrophil chemotaxis induced by IL-8.
Career Highlights
Throughout her career, Vilma Sabbatini has worked with notable companies, including Dompe S.p.a. Her innovative research has led to advancements in pharmaceutical formulations and therapeutic strategies, making her a key figure in her field.
Collaborations
Sabbatini has collaborated with esteemed colleagues such as Marcello Allegretti and Riccardo Bertini. These partnerships have contributed to the success of her research and the development of her patented inventions.
Conclusion
Vilma Sabbatini's contributions to pharmaceutical chemistry through her innovative patents highlight her role as a leading inventor in the field. Her work continues to pave the way for new treatments for inflammatory diseases, showcasing the importance of her research in improving patient outcomes.